Objective To observe the analgesic effects and safety of morphine combined low-dose ketamine with patient control subcutaneous analgesia(PCSA) for patieats with moderate to severe late cancer pain. Methods 60 patients with moderate to severe late phase cancer pain were randomly average divided into two groups (group Ⅰ and group Ⅱ). 30 patients of group Ⅰ were treated with morphine PCSA and 30 patients of group Ⅱ were treated lowdose ketamine plus morphine PCSA,respectively. The VAS(Visual Analogue Scale) of pain scores were evaluated after treatment 1 h、24 h、48 h. Effects and the rate of side effects were also comparred. Results There was no significant difference in VAS pains scores in each period. Morphine dosage in group Ⅰ (56.43 mmg) was significantly more than that in group Ⅱ (31.23mg) (x~2 =6. 18,P ＜0.05). Group Ⅱ :The incidence of nausea or vomiting was 4cases (13.3%) ,constipation was 2cases(6. 7%) ,drowsiness was 2cases(6. 7%) ,skin titillation was 0(0.0) ;but Group Ⅰ of it was 21 (70.0%), 18 (60.0%) ,9 (30.0%), 8 (26. 7%), The incidence of group Ⅱ was lower than group Ⅰ .Conclusion Small dosage ketamine combined with morphine patient control subcutaneous analgesia (PCSA) approach appears to provide a safe and effective method for advanced cancer patients with moderate to severe pain.

Objective To observe the therapeutic effect of stellate ganglion block for the treatment of facial paralysis. Methods 128 patients were randomly divided into two groups. Control group was treated by routine therapy , treatment group was treated by routine therapy plus stellate ganglion block. The effects of the two groups were evaluated by facial paralysis scale. Effective rate and cure rate as well as the course of therapy after treatment were also observed and compared. Results The cure rate of treatment group was 65% , effective rate was 98%. The cure rate of control group was 35% .effective rate was 82%. The cure rate and effective rate of treatment group were significantly higher than that of control group (P < 0. 05 ). The mean effective time and cure time of treatment group were shorter than the control group (P < 0.05). Conclusion Stellate ganglion block plus routine therapy produced better therapeutic effect and shortened the therapeutic course of facial paralysis.

Objective To explore the methods of therapy in lung cancer patients with bone metastases, and evaluate the effects and side effects of Strontium-89 palliative therapy in lung cancer patients with bone metastases. Methods About 56 cases of bronchiogenic cancer patients with bone metastases who did not receive any radiotherapy, according to 1.48×10~7 Bq/person/time, using standard intravenous injection ~(89)Sr as treatment. Follow-up 6 months, assess according to the following parameters: pain and frequency of pain were given quantized value and got pain score, using T test for comparing the pain score. According to before and after treatment bone imaging showed the size of focus and change of the number, upgrade focus therapy effect. Examine (CEA) and (NSE), using T test for changes before and after treatment. Using T test for changes of LEU and platelet after treatment. Results After treatment for 6 months, for 77 % patients are alleviating pain (43/56), the pain went off of 13 patents, account for 23 percent of the total. The pain score from 7.3±3.6 before treatment decrease to 5.3±3.4 after treatment, dropping obviously. After treatment, the focus regressed in 14 cases, decreased in 5 cases, total efficiency is 34 %. Before and after treatment, CEA from (33.64±18.15)μg/L obviously decreased to (t=4.26, P<0.01) to (21.36±11.65) μg/L, NSE from (27.16±10.12) μg/L obviously decreased to (t=4.26, P<0.05) to (12.56±4.23) μg/L. After treatment, LEU and platelet decreased to the lowest, LEU decreased about 27.9 %, platelet decreased about 19.7 %, after 3 months,normal rate of blood picture is 75 %(42/56). Conclusion The method of strontium-89 palliative therapy in lung cancer patients with bone metastases is good, safe and has little side effects, it can improve the quality of patients life.